For patients with estrogen receptor-positive and LNN early stage breast cancer, gene-expression profiling (e.g. Oncotype DX) is an accepted clinical strategy for assessing risk recurrence and in the selection for adjuvant chemotherapy treatments [24, 25]. The gene discussed is ESR1; the disease is breast carcinoma.